Abstract
Objective: Many patients with metastatic colorectal cancer (MCRC) cannot afford the targeted therapy in China. There is no standard treatment when these patients whose tumors relapsed following the first- and second- line chemotherapy. The goal of the present study is to evaluate the efficacy and safety of continuous intravenous infusion (CIV) of low-dose 5-fluorouracil5-FUfor heavily pretreated patients with MCRC. Methods: Twenty-three heavily pretreated patients with MCRC received 5-FU 200 mg/m2 per day as CIV for more than 30 days. Efficacy and safety was evaluated after one cycle of chemotherapy. Results: No patient achieved complete response (CR), 2 patients partial response (PR), 8 patients stable disease (SD), and 13 patients progression disease (PD). Response rate (RR) was 8.7%, disease control rateCR+PR+SD was 43.5%Toxicity was mild. Conclusion: This study showed that continuous venous infusion of low-dose 5-fluorouracil was moderately active and well tolerated in heavily pretreated patients with MCRC.
Keywords: Low-dose 5-fluorouracil, continuous intravenous infusion, metastatic colorectal cancer.
Graphical Abstract
Related Books
Frontiers in Clinical Drug Research - Anti-Cancer Agents
The Management of Metastatic Triple-Negative Breast Cancer: An Integrated and Expeditionary Approach
Cancer Genes
Cancer Medicine in an Ayurvedic Perspective: A Critical Overview
Cancer Genes
Anticancer Immunity: Reviewing the Potential of Probiotics
Probiotics in Anticancer Immunity
Phytonutrients in the Treatment of Gastrointestinal Cancer
Molecular Targets and Cancer Therapeutics (Part 2)
Molecular Targets and Cancer Therapeutics (Part 1)
32
1